The migraine therapeutics market share is expected to increase by USD 1.06 billion from 2020 to 2025, and the market’s growth momentum will accelerate at a CAGR of 5.3%.
This migraine therapeutics market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers migraine therapeutics market segmentations by product (drugs and devices), treatment (preventive treatment and abortive treatment) and geography (North America, Europe, Asia, and ROW). The migraine therapeutics market report also offers information on several market vendors, including AbbVie Inc., Amgen Inc., Eli Lilly and Co., eNeura Inc., GlaxoSmithKline Plc, Grunenthal GmbH, H. Lundbeck AS, Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Upsher-Smith Laboratories LLC among others.
What will the Migraine Therapeutics Market Size be During the Forecast Period?
Download the Free Report Sample to Unlock the Migraine Therapeutics Market Size for the Forecast Period and Other Important Statistics
Migraine Therapeutics Market: Key Drivers, Trends, and Challenges
The increase in the number of patients suffering from migraine is notably driving the migraine therapeutics market growth, although factors such as concerns related to the side effects of migraine drugs may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the migraine therapeutics industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Migraine Therapeutics Market Driver
The increase in the number of patients suffering from migraine is a major factor driving the migraine therapeutics market share growth. Migraine is a highly prevalent neurological disease across the world. Its prevalence is more in North America, followed by Europe and some parts of Africa and Asia. The overdose of pain-relief medicines can also lead to migraine. The frequent use of some medications can lead to the development of a disabling condition termed medication-overuse headache (MOH). Some of the other reasons that trigger migraine are lack of sleep, hunger, changes in the weather, excessive stimulation of the senses, and stress. Migraine usually begins during puberty or young adulthood. Women are considered to be more susceptible to migraine and less responsive to migraine treatment. The female reproductive hormone estrogen plays a major role in causing migraine. The fluctuations in estrogen levels affect the cells in the brain. Estrogen creates an electrical phenomenon in women's brain called cortical spreading depression, which is considered to be associated with migraine. The high prevalence of migraine across the world is expected to increase the demand for migraine therapeutics.
Key Migraine Therapeutics Market Trend
The growth in the number of migraine treatment awareness programs is another factor supporting the global migraine therapeutics market share growth. Migraine is a common and highly disabling neurological disorder. Various migraine treatment awareness programs are being conducted by several organizations for educating and helping patients with migraine. A few such organizations are The Migraine Trust, U.S. Pain Foundation, the American Migraine Foundation, M.A.G.N.U.M. Migraine Awareness Group: A National Understanding for Migraineurs, and the National Headache Foundation. For instance, the National Headache Foundation promotes June as the national migraine and headache awareness month. Every year, The Migraine Trust considers the week starting from the first Sunday in September as the migraine awareness week to raise awareness of the condition and to highlight the impact of migraine among people. The U.S. Pain Foundation teams up with Coalition For Headache And Migraine Patients (CHAMP) for National Migraine & Headache Awareness Month (MHAM) each year for creating awareness related to migraine. The American Migraine Foundation organizes the Move Against Migraine campaign that was aimed at increasing the awareness, advocacy, and funding for migraine in the US. Due to such programs and campaigns, the demand for the market will continue to grow.
Key Migraine Therapeutics Market Challenge
The concerns related to the side effects of migraine drugs will be a major challenge for the global migraine therapeutics market share growth during the forecast period. There are various risks associated with the therapeutics prescribed for migraine. Several migraine drugs have side effects, and the most common side effects are drowsiness, weight gain, insomnia, muscle weakness, chest pressure, warm sensations, and agitation. For instance, the consumption of triptans can lead to side effects such as sleepiness, fatigue, racing heartbeat, and nausea. Similarly, the consumption of topiramate leads to weakness, fatigue, dizziness, drowsiness, confusion, diarrhea, loss of appetite, impotence, and weightlessness. Some of the beta-blockers used for preventing migraine can lead to side effects such as depression, fatigue, nausea, insomnia, and lowered blood pressure. Therefore, the side effects of migraine drugs can hinder the growth of the global migraine therapeutics market during the forecast period.
This migraine therapeutics market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.
Parent Market Analysis
Technavio categorizes the global migraine therapuetics market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the migraine therapeutics market during the forecast period.
Who are the Major Migraine Therapeutics Market Vendors?
The report analyzes the market’s competitive landscape and offers information on several market vendors, including:
- AbbVie Inc.
- Amgen Inc.
- Eli Lilly and Co.
- eNeura Inc.
- GlaxoSmithKline Plc
- Grunenthal GmbH
- H. Lundbeck AS
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Upsher-Smith Laboratories LLC
This statistical study of the migraine therapeutics market encompasses successful business strategies deployed by the key vendors. The migraine therapeutics market is fragmented and the vendors are deploying growth strategies such as product launches to compete in the market.
Product Insights and News
- AbbVie Inc.- The company provides acute treatment for Migraine with or without Aura in adults, under the brand name UBRELVY.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The migraine therapeutics market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Migraine Therapeutics Market Value Chain Analysis
Our report provides extensive information on the value chain analysis for the migraine therapeutics market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
The value chain of global pharmaceutical market includes the following core components:
- Inputs
- Inbound logistics
- Operations
- Outbound logistics
- Marketing and sales
- Service
- Support activities
- Innovation
The report has further elucidated on other innovative approaches being followed by manufacturers to ensure a sustainable market presence.
Which are the Key Regions for Migraine Therapeutics Market?
For more insights on the market share of various regions Request for a FREE sample now!
38% of the market’s growth will originate from North America during the forecast period. US is the key market for migraine therapeutics market in North America. Market growth in this region will be slower than the growth of the market in Europe and Asia.
The rising healthcare expenditure will facilitate the migraine therapeutics market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
What are the Revenue-generating Product Segments in the Migraine Therapeutics Market?
To gain further insights on the market contribution of various segments Request for a FREE sample
The migraine therapeutics market share growth by the drugs segment will be significant during the forecast period. Factors such as increasing commercial approval of drugs and rising adoption of migraine prevention drugs are boosting the growth of the market share of drugs. Consumers are steadily opting for drugs such as beta-blockers and topiramate.
This report provides an accurate prediction of the contribution of all the segments to the growth of the migraine therapeutics market size and actionable market insights on post COVID-19 impact on each segment.
|
Migraine Therapeutics Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
120 |
|
Base year |
2020 |
|
Forecast period |
2021-2025 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 5.3% |
|
Market growth 2021-2025 |
$ 1.06 billion |
|
Market structure |
Fragmented |
|
YoY growth (%) |
4.82 |
|
Regional analysis |
North America, Europe, Asia, and ROW |
|
Performing market contribution |
North America at 38% |
|
Key consumer countries |
US, Germany, France, UK, and Japan |
|
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
|
Key companies profiled |
AbbVie Inc., Amgen Inc., Eli Lilly and Co., eNeura Inc., GlaxoSmithKline Plc, Grunenthal GmbH, H. Lundbeck AS, Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Upsher-Smith Laboratories LLC |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
What are the Key Data Covered in this Migraine Therapeutics Market Report?
- CAGR of the market during the forecast period 2021-2025
- Detailed information on factors that will drive migraine therapeutics market growth during the next five years
- Precise estimation of the migraine therapeutics market size and its contribution to the parent market
- Accurate predictions on upcoming trends and changes in consumer behavior
- The growth of the migraine therapeutics industry across North America, Europe, Asia, and ROW
- A thorough analysis of the market’s competitive landscape and detailed information on vendors
- Comprehensive details of factors that will challenge the growth of migraine therapeutics market vendors
We can help! Our analysts can customize this report to meet your requirements. Get in touch